Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

NCT Number	NCT07032103
Lead Sponsor	Samsung Medical Center
Conditions	Lymphoma
Enrollment	2,000 participants
Start Date	2022-06-01
Primary Completion	2028-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-22